Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

BACKGROUND: The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting ur...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet Infect Dis
Päätekijät: Koch, Till, Dahlke, Christine, Fathi, Anahita, Kupke, Alexandra, Krähling, Verena, Okba, Nisreen M A, Halwe, Sandro, Rohde, Cornelius, Eickmann, Markus, Volz, Asisa, Hesterkamp, Thomas, Jambrecina, Alen, Borregaard, Saskia, Ly, My L, Zinser, Madeleine E, Bartels, Etienne, Poetsch, Joseph S H, Neumann, Reza, Fux, Robert, Schmiedel, Stefan, Lohse, Ansgar W, Haagmans, Bart L, Sutter, Gerd, Becker, Stephan, Addo, Marylyn M
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier Ltd. 2020
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7172913/
https://ncbi.nlm.nih.gov/pubmed/32325037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(20)30248-6
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia